Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.5 USD | +4.19% | +0.95% | -30.67% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.